Does melatonin help save dopaminergic cells in MPTP-treated mice?

Parkinsonism and Related Disorders

Volumn 15, Issue 4, 2009, Pages 307-314

  Ma, Jeannine ^b   Shaw, Victoria E ^c   Mitrofanis, John ^a,b,c  

^a The Australian National University   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Basal ganglia; Cell death; Neuroprotection; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALDEHYDE; MELATONIN; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOCHEMISTRY; MALE; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NISSL STAINING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STEREOLOGY; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIOXIDANTS; BRAIN; CELL COUNT; CELL DEATH; CELL SIZE; DOPAMINE; DRUG INTERACTIONS; MALE; MELATONIN; MICE; MICE, INBRED BALB C; NEURONS; NEUROTOXINS; TYROSINE 3-MONOOXYGENASE;

EID: 64249129142     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.07.008     Document Type: Article

References (37)

1. Rinne J.O. Nigral degeneration in Parkinson's disease. Mov Disord 8 Suppl. 1 (1993) S31-S35
2. Blandini F., Nappi G., Tassorelli C., and Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62 (2000) 63-88
3. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 20 (2005) S11-S16
4. Wallace B.A., Ashkan K., Heise C.E., Foote K.D., Torres N., Mitrofanis J., et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 130 (2007) 2129-2145
5. Reiter R.J. Neuroendocrinology of melatonin. In: Miles A., Philbrick D.R.S., and Thompson C. (Eds). Melatonin - clinical perspectives (1988), Oxford University Press, Oxford 1-42
6. Ianas O., Olinescu R., and Badescu I. Melatonin involvement in oxidative processes. Endocrinologie 29 (1991) 147-153
7. Hara M., Yoshida M., Nishijima H., Yokosuka M., Iigo M., Ohtani-Kaneko R., et al. Melatonin a pineal secretory product with antioxidant properties protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 30 (2001) 129-138
8. Kim Y.S., Joo W.S., Jin B.K., Cho Y.H., Baik H.H., and Park C.W. Melatonin protects 6OHDA-induced neuronal death of nigrostriatal dopaminergic system. Neuroreport 13 (1998) 2387-2390
9. Antoli{dotless}n I., Mayo J.C., Sainz R.M., de los Angeles del Bri{dotless}o M., Herrera F., Marti{dotless}n V., et al. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 943 (2002) 163-173
10. Itzhak Y., Martin J.L., Dean Black M., and Ali S.F. Effect of melatonin on methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioural sensitization. Neuropharmacology 37 (1998) 781-791
11. Morgan W.W., and Nelson J.F. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. Brain Res 921 (2001) 115-121
12. Acuna-Castroviejo D., Coto-Montes A., Gaia Monti M., Ortiz G.G., and Reiter R.J. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 60 (1997) 23-29
13. Joo W.S., Jin B.K., Park C.W., Maeng S.H., and Kim Y.S. Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. Neuropharmacology 9 (1998) 4123-4126
14. Mayo J.C., Sainz R.M., Uria H., Antolin I., Esteban M.M., and Rodriguez C. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson disease. J Pineal Res 24 (1998) 179-192
15. Dabbeni-Sala F., Di Santo S., Franceschini D., Skaper S.D., and Giusti P. Melatonin protects against 6OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15 (2001) 164-170
16. Thomas B., and Mohanakumar K.P. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1236-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 36 (2004) 25-32
17. Sharma R., McMillan C.R., Tenn C.C., and Niles L.P. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson disease. Brain Res 1068 (2006) 230-236
18. Jin B.K., Shin D.Y., Jeong M.Y., Gwag M.R., Baik H.W., Yoon K.S., et al. Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenyl-pyridinium (MPP+) neurotoxicity in rats. Neurosci Lett 245 (1998) 61-64
19. Paxinos G., and Franklin K.B.J. The mouse brain in stereotaxic coordinates. 2nd ed. (2001), Academic Press, San Diego, CA
20. Aguirre J.A., Andbjer B., Gonzalez-Baron S., Hansson A., Stromberg I., Agnati L.F., et al. Group I mGluR antagonist AIDA protects nigral DA cells from MPTP-induced injury. Neuroreport 12 (2001) 2615-2617
21. Vasconcelos-Aguiar L.M., Nobre Jr. H.V., Macêdo D.S., Oliveira A.A., Freitas R.M., Vasconcelos S.M., et al. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol Biochem Behav 84 (2006) 415-419
22. Suganuma H., Hirano T., Arimoto Y., and Inakuma T. Effect of tomato intake on striatal monoamine level in a mouse model of experimental Parkinson's disease. J Nutr Sci Vitaminol 48 (2002) 251-254
23. Georgievska B., Kirik D., and Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177 (2002) 461-474
24. Riederer P., Gille G., Müller T., Przuntek H., Reichmann H., Riess O., et al. Practical importance of neuroprotection in Parkinson's disease. J Neurol 249 (2002) 53-56
25. Piallat B., Benazzouz A., and Benabid A.L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 8 (1996) 1408-1414
26. Ashkan K., Wallace B., Bell B.A., and Benabid A.L. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 1993-2003: where are we 10 years on?. Br J Neurosurg 18 (2004) 19-34
27. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., et al. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16 (2000) 135-142
28. Paul G., Meissner W., Rein S., Harnack D., Winter C., Hosmann K., et al. Removal of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 185 (2004) 272-280
29. Bjorklund A., Rosenblad C., Winkler C., and Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 4 (1997) 186-200
30. Mitrofanis J. Calbindin immunoreactivity in a subset of cat thalamic reticular neurones. J Neurocytol 21 (1992) 495-505
31. Fallon J.H., and Loughlin S.E. Monoamine innervation of the forebrain: collaterilisation. Brain Res Bull 9 (1982) 295-307
32. Shaw K.M., Stern G.M., and Sandler M. Melatonin and parkinsonism. Lancet 1 (1973) 271
33. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol 21 (2001) 605-616
34. Bordet R., Devos D., Brique S., Touitou Y., Guieu J.D., Libersa C., et al. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacology 26 (2003) 65-72
35. Guardiola-Lemaitre B. Toxicology of melatonin. J Biol Rhythms 12 (1997) 697-706
36. Anton-Tay F., Diaz J.L., and Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci I 10 (1971) 841-850
37. Willis G.L. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. Drug News Perspect 8 (2005) 437-444